방사선 치료 시장 : 세계 예측(2026-2032년)

The Radiotherapy Market is projected to grow by USD 15.72 billion at a CAGR of 7.73% by 2032.

Radiotherapy Executive Summary: Precision Oncology, Access, and Clinical Transformation

Radiotherapy is a cornerstone of modern oncology, used with surgery, systemic therapy, immunotherapy, and palliative care to treat a broad spectrum of solid tumors and selected hematologic malignancies. Clinical practice is shifting from conventional radiation delivery toward precision radiotherapy, including intensity-modulated radiotherapy, image-guided radiotherapy, stereotactic body radiotherapy, stereotactic radiosurgery, adaptive radiotherapy, proton therapy, brachytherapy, and hypofractionated regimens. These approaches aim to improve tumor control while reducing radiation exposure to surrounding healthy tissues.

Demand for radiotherapy is supported by the global cancer burden, population aging, improved screening, longer cancer survivorship, and growing clinical evidence for organ-preserving treatment pathways. The International Agency for Research on Cancer reported approximately 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, reinforcing the need for accessible, high-quality oncology infrastructure. International health agencies and radiation oncology organizations have also highlighted persistent gaps in radiotherapy availability, particularly across low- and middle-income countries, where shortages of linear accelerators, cobalt units where still used, brachytherapy capacity, trained radiation oncologists, medical physicists, dosimetrists, radiation therapists, and maintenance capability can delay care.

The radiotherapy landscape is increasingly defined by treatment precision, workflow automation, multidisciplinary planning, quality assurance, and patient-centered care. Health systems are prioritizing evidence-based protocols, safety culture, interoperability, radiation protection, and investment in workforce development to expand access while maintaining clinical quality.

Transformative Shifts in Radiotherapy Delivery and Cancer Care Pathways

The radiotherapy landscape is undergoing transformative shifts driven by precision medicine, digital oncology, and value-based cancer care. Image-guided and adaptive radiotherapy are enabling clinicians to account for daily anatomical changes, tumor motion, and treatment response, while stereotactic techniques support shorter treatment courses for selected indications such as early-stage lung cancer, brain metastases, prostate cancer, liver lesions, and oligometastatic disease. Hypofractionation has gained clinical acceptance in several tumor types because it can reduce patient visits, improve treatment convenience, and increase treatment capacity when supported by robust protocols and quality assurance.

Another major shift is the integration of radiotherapy into multidisciplinary cancer pathways. Radiation is increasingly sequenced or combined with systemic therapies, including chemotherapy, targeted therapy, hormone therapy, and immunotherapy, requiring closer coordination across tumor boards and care teams. Clinical interest in radiobiology, biomarkers, normal tissue toxicity prediction, and treatment personalization continues to influence research priorities.

Operationally, radiotherapy departments are moving toward digital treatment planning, automated contouring, cloud-enabled collaboration, electronic quality management, and data-driven workflow optimization. The emphasis has expanded beyond equipment acquisition to include uptime, cybersecurity, service support, staff training, patient throughput, incident learning systems, and standardized clinical governance. These shifts are making radiotherapy both more technologically advanced and more dependent on sustainable health-system capacity.

Cumulative Impact of Artificial Intelligence on Radiotherapy Workflows

Artificial intelligence is creating cumulative impact across the radiotherapy continuum, from imaging and treatment planning to quality assurance, workflow triage, and follow-up. AI-enabled tools can support auto-contouring of organs at risk and target structures, reduce repetitive planning tasks, assist dose optimization, and improve consistency across clinicians and treatment centers. In adaptive radiotherapy, AI can help accelerate replanning decisions by analyzing anatomical variation and supporting faster generation of clinically acceptable treatment plans.

The most meaningful impact of AI in radiotherapy is not limited to automation; it also supports standardization, scalability, and safety when implemented under clinical oversight. AI-assisted segmentation and planning can reduce manual workload for radiation oncology teams, potentially allowing scarce specialists to focus on complex decision-making, peer review, patient communication, and multidisciplinary care. Machine learning is also being explored for toxicity prediction, outcome modeling, motion management, image reconstruction, radiomics-based risk stratification, and real-world evidence generation.

However, responsible deployment remains essential. Radiotherapy is a high-risk clinical environment where algorithm performance, dataset representativeness, validation, explainability, bias management, regulatory compliance, and human-in-the-loop quality checks are critical. Institutions adopting AI need governance frameworks that include commissioning, ongoing monitoring, cybersecurity controls, audit trails, staff training, and clear accountability. AI's long-term value will depend on measurable improvements in treatment quality, workflow resilience, access, and patient outcomes rather than automation alone.

Key Regional Insights Across the Global Radiotherapy Landscape

Asia-Pacific is one of the most dynamic regions for radiotherapy due to a large cancer burden, expanding oncology infrastructure, and rising investment in tertiary cancer centers. Countries such as China, India, Japan, South Korea, and Australia are advancing image-guided radiotherapy, stereotactic techniques, brachytherapy, and particle therapy capabilities, although access remains uneven between urban and rural areas. Workforce development, reimbursement coverage, equipment distribution, and treatment waiting times remain central policy considerations across the region.

Europe benefits from mature radiation oncology networks, cross-border research collaboration, structured cancer plans, and strong clinical protocol development. European health systems are advancing hypofractionation, adaptive radiotherapy, survivorship care, quality registries, and evidence-based treatment standardization while managing aging equipment replacement, staffing constraints, and differences in access across national health systems. North America maintains a highly advanced radiotherapy ecosystem supported by comprehensive cancer centers, established clinical guidelines, strong adoption of stereotactic radiotherapy and proton therapy, and active clinical research in adaptive treatment and radiotherapy-immunotherapy combinations. The United States and Canada emphasize quality assurance, accreditation, multidisciplinary oncology pathways, and technology-enabled care coordination, while also addressing affordability, rural access, and workforce pressures.

Latin America continues to improve radiotherapy capacity through public cancer control programs, modernization of equipment, and regional training initiatives. Brazil and Mexico play important roles in expanding oncology services, yet disparities persist across public and private systems, remote geographies, and specialist availability. Africa faces the most significant access challenges, with several countries still experiencing limited radiotherapy infrastructure, long travel distances for treatment, and shortages of trained personnel. Regional progress depends on sustainable financing, maintenance programs, training pipelines, international partnerships, and integration of radiotherapy into national cancer control plans.

The Middle East is investing in specialized oncology infrastructure, particularly in Gulf countries where national cancer strategies are strengthening access to advanced radiotherapy and multidisciplinary cancer care. Across the region, priorities include early diagnosis, referral efficiency, technology modernization, medical physics capacity, and alignment of radiotherapy services with broader noncommunicable disease strategies.

Key Group Insights Shaping Radiotherapy Access and Innovation

NATO member countries show strong overlap with advanced European and North American health systems, where radiotherapy readiness, resilient medical supply chains, cybersecurity, and disaster-prepared oncology services are increasingly relevant to continuity of care. Within the G7, mature oncology systems generally lead in advanced radiotherapy research, clinical guideline development, proton therapy, adaptive radiotherapy, AI-enabled workflow exploration, and long-term survivorship programs, while also addressing aging populations, cost containment, workforce shortages, and equitable access outside major urban centers.

European Union countries benefit from coordinated cancer policy initiatives, regulatory standards, research networks, cross-border collaboration, and workforce mobility, enabling broader uptake of evidence-based radiotherapy protocols and quality improvement programs. EU-level cancer initiatives have reinforced priorities around screening, comprehensive cancer centers, data infrastructure, pediatric and rare cancers, and reduction of inequalities in diagnosis and treatment access. BRICS countries represent a large share of the global cancer burden and face diverse radiotherapy access challenges, from high-volume urban oncology hubs to underserved rural regions. Their priorities include equipment expansion, local workforce training, cost-effective treatment protocols, brachytherapy availability, and digital planning tools that can improve throughput.

ASEAN countries are prioritizing cancer control capacity as cancer incidence rises with population growth, aging, and lifestyle transitions. Radiotherapy development across the group is marked by wide variation, with advanced services concentrated in major urban hospitals while rural populations often face travel, waiting time, and affordability barriers. Regional collaboration in training, quality assurance, and technology transfer is important for improving equitable access. The GCC is strengthening radiotherapy services through investments in modern oncology centers, national health transformation programs, and specialized cancer care pathways. The region's focus on noncommunicable disease management, early diagnosis, and medical infrastructure modernization supports adoption of image-guided radiotherapy, stereotactic techniques, and multidisciplinary tumor boards.

Key Country Insights in Radiotherapy Development and Adoption

The United States has one of the most technologically advanced radiotherapy environments, with broad use of intensity-modulated radiotherapy, stereotactic radiosurgery, stereotactic body radiotherapy, proton therapy in selected centers, and strong integration of clinical trials. Canada emphasizes guideline-driven cancer care, provincial cancer agencies, quality assurance, and equitable access across large geographies, while Mexico continues to expand oncology capacity with ongoing needs in public-sector access, workforce availability, and timely treatment initiation.

Brazil is a central radiotherapy hub in Latin America, supported by national cancer institutions and expanding oncology networks, although regional disparities affect access. The United Kingdom has advanced national radiotherapy modernization programs, hypofractionation adoption, and data-driven cancer service planning. Germany maintains a strong radiotherapy base supported by academic medicine, technology adoption, and clinical research, while France combines comprehensive cancer networks with active use of precision radiotherapy and proton therapy for selected indications. Russia has been modernizing oncology infrastructure and expanding access to radiotherapy services, with continued emphasis on regional cancer center development. Italy and Spain have mature radiation oncology systems with strong participation in European clinical research, quality assurance, and multidisciplinary oncology care.

China is rapidly expanding radiotherapy infrastructure and clinical expertise to address a substantial cancer burden, with growing adoption of image-guided and stereotactic techniques in major centers. India faces high demand for accessible radiotherapy and continues to strengthen public oncology capacity, indigenous training, and cost-conscious treatment models. Japan is recognized for advanced radiotherapy, particle therapy expertise, and aging-related cancer care needs. Australia combines strong clinical governance with regional cancer networks and telehealth-enabled support for remote communities. South Korea has a highly developed cancer care system, widespread technology adoption, and active research in precision oncology and advanced radiotherapy workflows.

Actionable Recommendations for Radiotherapy Industry Leaders

Industry leaders should prioritize access, safety, and clinical value when shaping radiotherapy strategies. Investment decisions should account for the full treatment ecosystem, including equipment uptime, service contracts, treatment planning systems, imaging integration, cybersecurity, radiation protection, and quality assurance. Advanced equipment without trained staff, maintenance capacity, and standardized protocols can create bottlenecks rather than improve care.

Organizations should strengthen workforce pipelines for radiation oncologists, medical physicists, dosimetrists, radiation therapists, oncology nurses, engineers, and data specialists. Partnerships with academic centers, professional societies, and public health agencies can support training, peer review, credentialing, protocol harmonization, and incident learning. Leaders should also adopt patient-centered operating models that reduce waiting times, support hypofractionated treatment where clinically appropriate, improve navigation, and address financial and geographic barriers.

Digital transformation should be pursued with disciplined governance. AI-enabled radiotherapy tools require local validation, continuous monitoring, and clear clinical accountability. Health systems should build interoperable data environments, standardize nomenclature, and use real-world evidence to assess treatment quality, toxicity, and outcomes. For emerging markets and underserved regions, scalable models such as hub-and-spoke networks, remote planning support, regional maintenance programs, shared training platforms, and phased technology deployment can improve resilience and expand access to lifesaving radiotherapy.

Research Methodology for Evidence-Based Radiotherapy Insights

This executive summary is developed through a structured secondary research approach using verified and data-backed sources, including international cancer agencies, public health authorities, peer-reviewed oncology literature, clinical guideline bodies, radiation oncology professional organizations, and national cancer control resources. The analysis emphasizes validated evidence on cancer burden, radiotherapy access, clinical practice evolution, technology adoption, workforce needs, artificial intelligence applications, and regional healthcare infrastructure.

The methodology excludes market sizing, market share analysis, revenue estimates, and forecasting. Instead, it focuses on qualitative and evidence-based assessment of industry dynamics, clinical transformation, policy direction, and operational priorities. Regional, group, and country insights are interpreted through the lens of cancer epidemiology, healthcare capacity, access equity, treatment technology, reimbursement structures, workforce availability, maintenance readiness, and quality assurance practices.

To support relevance and industry usability, terminology reflects established radiotherapy and radiation oncology keywords, including precision radiotherapy, image-guided radiotherapy, stereotactic body radiotherapy, adaptive radiotherapy, proton therapy, brachytherapy, artificial intelligence in radiotherapy, oncology workflow, treatment planning, radiation oncology quality assurance, and cancer care access. Findings are synthesized to provide executive-level clarity for healthcare leaders, technology planners, policymakers, and oncology stakeholders.

Conclusion: Radiotherapy's Role in the Future of Precision Oncology

Radiotherapy remains essential to comprehensive cancer care, and its role is expanding as oncology shifts toward precision treatment, shorter regimens, adaptive workflows, and integrated multidisciplinary pathways. The sector's progress is being shaped by clinical evidence, artificial intelligence, advanced imaging, treatment planning automation, workforce development, and policy-driven efforts to close access gaps.

The most important strategic challenge is balancing innovation with equitable delivery. Advanced radiotherapy can improve precision and patient experience, but its benefits depend on sustainable infrastructure, trained professionals, quality assurance, maintenance, reimbursement alignment, and responsible digital governance. Regions and countries that combine technology adoption with system-level planning are better positioned to improve radiotherapy availability, safety, and outcomes.

For industry leaders, the path forward is clear: strengthen capacity, validate innovation, expand workforce capabilities, and design patient-centered radiotherapy services that are resilient, interoperable, and clinically accountable. As cancer incidence continues to challenge health systems worldwide, radiotherapy will remain a critical pillar of accessible, evidence-based, and precision-driven oncology care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Radiotherapy Market, by Radiotherapy Type

• 7.1. Introduction
• 7.2. External Beam Radiotherapy
  • 7.2.1. X Ray Radiotherapy
  • 7.2.2. 3D Conformal Radiation Therapy
  • 7.2.3. Image Guided Radiotherapy
  • 7.2.4. Intensity Modulated Radiotherapy
  • 7.2.5. Stereotactic Radiosurgery
  • 7.2.6. Stereotactic Body Radiotherapy
• 7.3. Internal Radiotherapy
  • 7.3.1. High Dose Rate Brachytherapy
  • 7.3.2. Low Dose Rate Brachytherapy
• 7.4. Intraoperative Radiotherapy

8. Radiotherapy Market, by Component

• 8.1. Introduction
• 8.2. Hardware
  • 8.2.1. Brachytherapy Afterloaders
  • 8.2.2. Gamma Knife Systems
  • 8.2.3. Imaging & Guidance Systems
  • 8.2.4. Linear Accelerators (LINACs)
  • 8.2.5. Multileaf Collimators (MLCs)
  • 8.2.6. Proton Therapy Systems
• 8.3. Service
  • 8.3.1. Maintenance & Calibration
  • 8.3.2. Training & Consulting
• 8.4. Software
  • 8.4.1. Treatment Planning Systems
  • 8.4.2. Dose Calculation Software

9. Radiotherapy Market, by Procedure Type

• 9.1. Introduction
• 9.2. Curative Radiotherapy
• 9.3. Palliative Radiotherapy
• 9.4. Adjuvant Radiotherapy

10. Radiotherapy Market, by Application

• 10.1. Introduction
• 10.2. Brain Tumors
• 10.3. Breast Cancer
• 10.4. Cervical Cancer
• 10.5. Gastrointestinal Cancer
  • 10.5.1. Colorectal Cancer
  • 10.5.2. Esophageal Cancer
  • 10.5.3. Pancreatic Cancer
  • 10.5.4. Liver Cancer
• 10.6. Head & Neck Cancer
• 10.7. Lung Cancer
• 10.8. Prostate Cancer
• 10.9. Spine Cancer

11. Radiotherapy Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Surgical Centers
• 11.3. Hospitals
• 11.4. Specialty Clinics
• 11.5. Cancer Research Institutes

12. Radiotherapy Market, by Region

• 12.1. Asia-Pacific
• 12.2. Europe
• 12.3. North America
• 12.4. Latin America
• 12.5. Africa
• 12.6. Middle East

13. Radiotherapy Market, by Group

• 13.1. NATO
• 13.2. G7
• 13.3. European Union
• 13.4. BRICS
• 13.5. ASEAN
• 13.6. GCC

14. Radiotherapy Market, by Country

• 14.1. United States
• 14.2. China
• 14.3. Germany
• 14.4. Japan
• 14.5. India
• 14.6. United Kingdom
• 14.7. France
• 14.8. Canada
• 14.9. Italy
• 14.10. Australia
• 14.11. Brazil
• 14.12. South Korea
• 14.13. Mexico
• 14.14. Russia
• 14.15. Spain

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Siemens Healthineers AG
• 16.2. Elekta AB
• 16.3. Accuray Incorporated
• 16.4. IBA Dosimetry GmbH
• 16.5. Hitachi, Ltd.
• 16.6. Mevion Medical Systems, Inc.
• 16.7. ViewRay Technologies, Inc.
• 16.8. Mitsubishi Electric Corporation
• 16.9. Carl Zeiss AG
• 16.10. Panacea Medical Technologies Pvt. Ltd.
• 16.11. Agilent Technologies Inc.
• 16.12. BEBIG Medical GmbH
• 16.13. Brainlab AG
• 16.14. Canon Medical Systems Corporation
• 16.15. Cardinal Health, Inc.
• 16.16. CivaTech Oncology Inc.
• 16.17. CQ Medical
• 16.18. Epsilon Elektronik
• 16.19. GE HealthCare Technologies Inc.
• 16.20. Healvita Group GmbH
• 16.21. IntraOp Medical, Inc.
• 16.22. Klarity Medical Products
• 16.23. Koninklijke Philips N.V.
• 16.24. Leo Cancer Care
• 16.25. RaySearch Laboratories AB
• 16.26. RefleXion Medical Inc.
• 16.27. Revvity, Inc.
• 16.28. Sumitomo Heavy Industries Ltd.
• 16.29. Theragenics Corporation
• 16.30. Toshiba Corporation
• 16.31. Vision RT Ltd.
• 16.32. Xstrahl Limited